MedTrace Logo

Silodosin vs Placebo in the Treatment of Female LUTS

NCT06114979 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 278

Last updated 2023-11-02

No results posted yet for this study

Summary

This trial will be conducted to study the efficacy and safety of Silodosin in the treatment of female lower urinary tract symptoms.

Conditions

  • Lower Urinary Tract Symptoms

Interventions

DRUG

Silodosin

Each patient will receive 8 mg of silodosin tablet once daily.

DRUG

Placebo

Each patient will receive placebo tablet.

Sponsors & Collaborators

  • Amiri Hospital

    collaborator OTHER_GOV

  • Mansoura University

    lead OTHER

Principal Investigators

  • Tariq F AL-Shaiji, MD · Amiri Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-01
Primary Completion
2024-10-30
Completion
2024-12-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06114979 on ClinicalTrials.gov